WO2001039792A3 - The use of caspase 9 inhibitors to treat ocular neural pathology - Google Patents

The use of caspase 9 inhibitors to treat ocular neural pathology Download PDF

Info

Publication number
WO2001039792A3
WO2001039792A3 PCT/US2000/031471 US0031471W WO0139792A3 WO 2001039792 A3 WO2001039792 A3 WO 2001039792A3 US 0031471 W US0031471 W US 0031471W WO 0139792 A3 WO0139792 A3 WO 0139792A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
caspase
treat ocular
ocular neural
neural pathology
Prior art date
Application number
PCT/US2000/031471
Other languages
French (fr)
Other versions
WO2001039792A2 (en
Inventor
Mark R Hellberg
Iok-Hou Pang
Jon C Nixon
Original Assignee
Alcon Universal Ltd
Mark R Hellberg
Pang Iok Hou
Jon C Nixon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Universal Ltd, Mark R Hellberg, Pang Iok Hou, Jon C Nixon filed Critical Alcon Universal Ltd
Priority to AU19205/01A priority Critical patent/AU1920501A/en
Publication of WO2001039792A2 publication Critical patent/WO2001039792A2/en
Publication of WO2001039792A3 publication Critical patent/WO2001039792A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

The invention provides pharmaceutical compositions containing caspase 9 inhibitors and methods of using these compositions to prevent or ameliorate ocular neural tissue disease, damage or disorder.
PCT/US2000/031471 1999-12-03 2000-11-16 The use of caspase 9 inhibitors to treat ocular neural pathology WO2001039792A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19205/01A AU1920501A (en) 1999-12-03 2000-11-16 The use of caspase 9 inhibitors to treat ocular neural pathology

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16891499P 1999-12-03 1999-12-03
US60/168,914 1999-12-03

Publications (2)

Publication Number Publication Date
WO2001039792A2 WO2001039792A2 (en) 2001-06-07
WO2001039792A3 true WO2001039792A3 (en) 2002-05-10

Family

ID=22613475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031471 WO2001039792A2 (en) 1999-12-03 2000-11-16 The use of caspase 9 inhibitors to treat ocular neural pathology

Country Status (2)

Country Link
AU (1) AU1920501A (en)
WO (1) WO2001039792A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815541B1 (en) * 2000-10-24 2008-02-29 Lipha USE OF PERICYTE APOPTOSIS INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC RETINOPATHY
CN101336887A (en) 2002-12-04 2009-01-07 参天制药株式会社 Drug delivery system using subconjunctival depot
FR2878522B1 (en) 2004-12-01 2008-04-18 Merck Sante Soc Par Actions Si NEW SPECIFIC INHIBITORS OF CASPAS-10
AU2007329539A1 (en) * 2006-12-01 2008-06-12 George Mason University Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2012061045A2 (en) * 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
CA2888805C (en) 2011-10-21 2020-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
WO2013188676A2 (en) * 2012-06-13 2013-12-19 The Trustees Of Columbia University In The City Of New York Intranasal delivery of cell permeant therapeutics for the treatment of edema
EP3481395A4 (en) * 2016-07-11 2020-05-13 The Trustees of Columbia University in the City of New York Ocular delivery of cell permeant therapeutics for the treatment of retinal edema
WO2020223212A2 (en) * 2019-04-29 2020-11-05 The Trustees Of Columbia University In The City Of New York Compositions and methods for preventing or reducing inflammation by inhibiting caspase-9

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
WO1999047154A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
WO1999065937A2 (en) * 1998-06-16 1999-12-23 Thomas Jefferson University Truncated apaf-1 and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
WO1999047154A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
WO1999065937A2 (en) * 1998-06-16 1999-12-23 Thomas Jefferson University Truncated apaf-1 and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEERE HELEN M ET AL: "Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome.", NATURE CELL BIOLOGY, vol. 2, no. 8, August 2000 (2000-08-01), pages 469 - 475, XP001010050, ISSN: 1465-7392 *
DEVERAUX QUINN L ET AL: "Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 18, no. 19, 1 October 1999 (1999-10-01), pages 5242 - 5251, XP002170857, ISSN: 0261-4189 *
DONG ZHENG ET AL: "Serine protease inhibitors suppress cytochrome c-mediated caspase-9 activation and apoptosis during hypoxia-reoxygenation.", BIOCHEMICAL JOURNAL, vol. 347, no. 3, 1 May 2000 (2000-05-01), pages 669 - 677, XP002170858, ISSN: 0264-6021 *
HU Y ET AL: "Bcl-XL interacts with Apaf -1 and inhibits Apaf -1-dependent caspase -9 activation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 95, no. 8, 14 April 1998 (1998-04-14), pages 4386 - 4391, XP002126632, ISSN: 0027-8424 *
SEATON A D ET AL: "Elevation of retinal heat shock protein 70 reduces post-ischemic edema in acute retinal artery occlusion.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 37, no. 3, 1996, 1996 Annual Meeting of the Association for Research in Vision and Ophthalmology;Fort Lauderdale, Florida, USA; April 21-26, 1996, pages S968, XP002170856, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
AU1920501A (en) 2001-06-12
WO2001039792A2 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
AU7186501A (en) Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
HK1043019A1 (en) Compositions and methods for prevention and treatment of protozoal disease.
WO2001039792A3 (en) The use of caspase 9 inhibitors to treat ocular neural pathology
ZA200201819B (en) Preventive and therapeutic agents for eye diseases.
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
AUPQ622600A0 (en) Treatment and/or prevention of ocular pain
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
MXPA03006776A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease.
NL1010351A1 (en) Esters of carotenoids for use in the prevention and treatment of eye diseases.
EP0744176A3 (en) Methods for inhibiting bone loss
HK1047549A1 (en) Il6ril6 chimera for the treatment of neurodegeneraive diseases.
MXPA02005959A (en) Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage.
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
ATE314064T1 (en) L-ACETYLCARNITINE AND L-PROPIONYLCARNITINE COMPOSITION FOR THE PREVENTION AND TREATMENT OF KIDNEY DISORDERS AND KIDNEY DISEASE
DE69739190D1 (en) MEDICAMENT FOR THE TREATMENT OF OCULAR CRUSH DISEASES
ID20165A (en) USE OF ACID 2- (3,4-DIMETOXICINAMOIL) AMINOBENZOAT FOR MAKING MEDICINES FOR TREATMENT OR PREVENTION OF RESTENOSIS
WO2001037832A3 (en) Combination of riluzole and gabapentin and use thereof as medicine
EP0891778A3 (en) Agents for the prevention and/or treatment of radiation-induced disorders
HUP0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
AU2002348324A1 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 46566
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.
ID28817A (en) USE OF TETRAHIDROPIRIDIN (OR 4-HIDROPIPERIDIN) -BUTILAZOL DRUGS IN THE MAKING OF DRUGS FOR PAIN TREATMENT

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase